Bradanicline, also known as TC-5619 and ATA-101, is Alpha-7 Nicotinic Receptor Agonist. Bradanicline showed cognitive enhancing effects in animal studies, and was being developed as a potential treatment for schizophrenia and attention deficit disorder. TC-5619 binds with very high affinity to the alpha7 subtype and is a potent full agonist. TC-5619 has little or no activity at other nicotinic receptors, including the alpha4beta2, ganglionic (alpha3beta4) and muscle subtypes. TC-5619 acted both alone and synergistically with the antipsychotic clozapine to correct impaired pre-pulse inhibition (PPI) and social behavior which model positive and negative symptoms, respectively. TC-5619 significantly reversed apomorphine-induced PPI deficits.
MedKoo Cat#: 319639
Name: Bradanicline HCl
CAS#: 1111941-90-2 (HCl)
Chemical Formula: C22H24ClN3O2
Exact Mass: 0.0000
Molecular Weight: 397.90
Elemental Analysis: C, 66.41; H, 6.08; Cl, 8.91; N, 10.56; O, 8.04
The following data is based on the product molecular weight 397.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
